FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898633757> ?p ?o ?g. }

• W2898633757 endingPage "768" @default.
• W2898633757 startingPage "753" @default.
• W2898633757 abstract "To systematically review the evidence regarding the efficacy of vaccines or immunostimulants in reducing the recurrence rate of urinary tract infections (UTIs).The Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE), PubMed, Cochrane Library, World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal, and conference abstracts were searched up to January 2018 for English-titled citations. Randomised placebo-controlled trials evaluating UTI recurrence rates in adult patients with recurrent UTIs treated with a vaccine were selected by two independent reviewers according to the Population, Interventions, Comparators, and Outcomes (PICO) criteria. Differences in recurrence rates in study populations for individual trials were calculated and pooled, and risk ratios (RRs) using random effects models were calculated. Risk of bias was assessed using the Cochrane Collaboration's tool and heterogeneity was assessed using chi-squared and I2 testing. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence (QOE) and summarise findings.In all, 599 records were identified, of which 10 studies were included. A total of 1537 patients were recruited and analysed, on whom data were presented. Three candidate vaccines were studied: Uro-Vaxom® (OM Pharma, Myerlin, Switzerland), Urovac® (Solco Basel Ltd, Basel, Switzerland), and ExPEC4V (GlycoVaxyn AG, Schlieren, Switzerland). At trial endpoint, the use of vaccines appeared to reduce UTI recurrence compared to placebo (RR 0.74, 95% confidence interval [CI] 0.67-0.81; low QOE). Uro-Vaxom showed the greatest reduction in UTI recurrence rate; the maximal effect was seen at 3 months compared with 6 months after initial treatment (RR 0.67, 95% CI 0.57-0.78; and RR 0.78, 95% CI 0.69-0.88, respectively; low QOE). Urovac may also reduce risk of UTI recurrence (RR 0.75, 95% CI 0.63-0.89; low QOE). ExPEC4V does not appear to reduce UTI recurrence compared to placebo at study endpoint (RR 0.82, 95% CI 0.62-1.10; low QOE). Substantial heterogeneity was observed across the included studies (chi-squared = 54.58; P < 0.001, I2 = 84%).While there is evidence for the efficacy of vaccines in patients with recurrent UTIs, significant heterogeneity amongst these studies renders interpretation and recommendation for routine clinical use difficult at present. Further randomised trials using consistent definitions and endpoints are needed to study the long-term efficacy and safety of vaccines for infection prevention in patients with recurrent UTIs." @default.
• W2898633757 created "2018-11-09" @default.
• W2898633757 creator A5018761294 @default.
• W2898633757 creator A5028270539 @default.
• W2898633757 creator A5042527926 @default.
• W2898633757 creator A5050922820 @default.
• W2898633757 creator A5068751414 @default.
• W2898633757 creator A5084295250 @default.
• W2898633757 date "2018-12-19" @default.
• W2898633757 modified "2023-10-17" @default.
• W2898633757 title "Vaccines for the prevention of recurrent urinary tract infections: a systematic review" @default.
• W2898633757 cites W127809831 @default.
• W2898633757 cites W2031833328 @default.
• W2898633757 cites W2042556618 @default.
• W2898633757 cites W204438897 @default.
• W2898633757 cites W2054116251 @default.
• W2898633757 cites W2066110036 @default.
• W2898633757 cites W2072310050 @default.
• W2898633757 cites W2073144086 @default.
• W2898633757 cites W2094690326 @default.
• W2898633757 cites W2113884517 @default.
• W2898633757 cites W2121014417 @default.
• W2898633757 cites W2152881784 @default.
• W2898633757 cites W2164785842 @default.
• W2898633757 cites W2302483558 @default.
• W2898633757 cites W2414688552 @default.
• W2898633757 cites W2590315902 @default.
• W2898633757 cites W2770218228 @default.
• W2898633757 doi "https://doi.org/10.1111/bju.14606" @default.
• W2898633757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30378242" @default.
• W2898633757 hasPublicationYear "2018" @default.
• W2898633757 type Work @default.
• W2898633757 sameAs 2898633757 @default.
• W2898633757 citedByCount "50" @default.
• W2898633757 countsByYear W28986337572019 @default.
• W2898633757 countsByYear W28986337572020 @default.
• W2898633757 countsByYear W28986337572021 @default.
• W2898633757 countsByYear W28986337572022 @default.
• W2898633757 countsByYear W28986337572023 @default.
• W2898633757 crossrefType "journal-article" @default.
• W2898633757 hasAuthorship W2898633757A5018761294 @default.
• W2898633757 hasAuthorship W2898633757A5028270539 @default.
• W2898633757 hasAuthorship W2898633757A5042527926 @default.
• W2898633757 hasAuthorship W2898633757A5050922820 @default.
• W2898633757 hasAuthorship W2898633757A5068751414 @default.
• W2898633757 hasAuthorship W2898633757A5084295250 @default.
• W2898633757 hasBestOaLocation W28986337571 @default.
• W2898633757 hasConcept C126322002 @default.
• W2898633757 hasConcept C142724271 @default.
• W2898633757 hasConcept C17744445 @default.
• W2898633757 hasConcept C199539241 @default.
• W2898633757 hasConcept C203092338 @default.
• W2898633757 hasConcept C204787440 @default.
• W2898633757 hasConcept C27081682 @default.
• W2898633757 hasConcept C2776478404 @default.
• W2898633757 hasConcept C2779473830 @default.
• W2898633757 hasConcept C2908647359 @default.
• W2898633757 hasConcept C44249647 @default.
• W2898633757 hasConcept C535046627 @default.
• W2898633757 hasConcept C71924100 @default.
• W2898633757 hasConcept C77411442 @default.
• W2898633757 hasConcept C82789193 @default.
• W2898633757 hasConcept C95190672 @default.
• W2898633757 hasConcept C99454951 @default.
• W2898633757 hasConceptScore W2898633757C126322002 @default.
• W2898633757 hasConceptScore W2898633757C142724271 @default.
• W2898633757 hasConceptScore W2898633757C17744445 @default.
• W2898633757 hasConceptScore W2898633757C199539241 @default.
• W2898633757 hasConceptScore W2898633757C203092338 @default.
• W2898633757 hasConceptScore W2898633757C204787440 @default.
• W2898633757 hasConceptScore W2898633757C27081682 @default.
• W2898633757 hasConceptScore W2898633757C2776478404 @default.
• W2898633757 hasConceptScore W2898633757C2779473830 @default.
• W2898633757 hasConceptScore W2898633757C2908647359 @default.
• W2898633757 hasConceptScore W2898633757C44249647 @default.
• W2898633757 hasConceptScore W2898633757C535046627 @default.
• W2898633757 hasConceptScore W2898633757C71924100 @default.
• W2898633757 hasConceptScore W2898633757C77411442 @default.
• W2898633757 hasConceptScore W2898633757C82789193 @default.
• W2898633757 hasConceptScore W2898633757C95190672 @default.
• W2898633757 hasConceptScore W2898633757C99454951 @default.
• W2898633757 hasIssue "5" @default.
• W2898633757 hasLocation W28986337571 @default.
• W2898633757 hasLocation W28986337572 @default.
• W2898633757 hasOpenAccess W2898633757 @default.
• W2898633757 hasPrimaryLocation W28986337571 @default.
• W2898633757 hasRelatedWork W1885119863 @default.
• W2898633757 hasRelatedWork W2014943083 @default.
• W2898633757 hasRelatedWork W2073750123 @default.
• W2898633757 hasRelatedWork W2217553306 @default.
• W2898633757 hasRelatedWork W2374685850 @default.
• W2898633757 hasRelatedWork W2592774827 @default.
• W2898633757 hasRelatedWork W2626084264 @default.
• W2898633757 hasRelatedWork W2903890959 @default.
• W2898633757 hasRelatedWork W3106934121 @default.
• W2898633757 hasRelatedWork W4379197432 @default.
• W2898633757 hasVolume "123" @default.
• W2898633757 isParatext "false" @default.

• next